Risk Of Developing Liver Cancer After HCV Treatment

Sunday, July 23, 2017

Vosevi - Frequently Asked Questions & Gilead's My Support Path® VOSEVI Program

PROJECT INFORM  
Vosevi: Frequently Asked Questions
These frequently asked questions will help you understand what Vosevi is, how it works, and help you decide if it is the right medication for you.

FDA
Prescribing Information

Gilead's Patient Support Program - Support Path®
To support these patients and their families, Gilead's U.S. Support Path® program provides information regarding access and reimbursement coverage options to patients in the United States who need assistance with coverage for their Gilead HCV medications, including Vosevi. Support Path conducts benefits investigations and provides patients with information regarding their insurance options.

Further, the Vosevi Co-pay Coupon Program offers co-pay assistance for eligible patients with private insurance who need assistance paying for out-of-pocket medication costs.

Gilead's Support Path® Program
Start Page - Support Path

My Support Path® VOSEVI Program
VOSEVI 

Eligible patients may pay no more than $5 per co-pay for VOSEVI
Restrictions apply. To check your eligibility, please call 1-855-7-MYPATH (1-855-769-7284) and speak with a VOSEVI Support Path® specialist, Monday through Friday from 9AM to 8PM Eastern Time.
  • Not valid for patients enrolled in government healthcare prescription drug programs, such as Medicare Part D and Medicaid. Patients in the coverage gap known as the "donut hole" also are not eligible
  • The HARVONI, EPCLUSA, SOVALDI, and VOSEVI co-pay coupon programs will cover the out-of-pocket costs for HARVONI, EPCLUSA, SOVALDI, and VOSEVI prescriptions up to a maximum of 25% of the catalog price of a 12-week regimen of HARVONI, EPCLUSA, SOVALDI, or VOSEVI

IMPORTANT FACTS
This is only a brief summary of important information about VOSEVI and does not replace talking to your healthcare provider about your condition and your treatment

News & Updates 

No comments:

Post a Comment